A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma (NCT05625399)
RELATIVITY-127
This trial is No longer recruiting
Registration number NCT05625399
Program & service
This trial is being run with the Cancer service, and as part of the Medical Oncology program.
Trial phase
Phase 3
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Associate Professor Andrew Haydon
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR